Gut Inflammation Blend (BPC-157, KPV, PEA, Tributyrin)
Also known as: Gut Inflammation Blend, Gastro Inflammation Research Formula, Gastro Inflammation Blend (BPC-157, KPV, N-Acetyl Larazotide)
A multi-component research blend combining the cytoprotective peptide BPC-157 with the anti-inflammatory tripeptide KPV plus fatty-acid mediators aimed at gastrointestinal mucosal repair. It is studied for its combined effects on gut-barrier integrity and local inflammation.
Last updated
Mechanism of Action
BPC-157 upregulates angiogenic and growth-factor signaling (VEGFR2, the nitric oxide system, and the EGR-1/FAK pathways) to accelerate epithelial and vascular repair. KPV, the C-terminal tripeptide of alpha-MSH, suppresses NF-kB and pro-inflammatory cytokine transcription and is transported across enterocytes via the PepT1 transporter. Palmitoylethanolamide (PEA) acts on PPAR-alpha and indirectly on cannabinoid-related receptors to dampen mast-cell and microglial inflammation, while tributyrin delivers butyrate as a histone-deacetylase inhibitor and energy substrate for colonocytes. The combination targets barrier integrity and mucosal inflammation through complementary pathways.
- Half-life
- Variable by component; BPC-157 has a short plasma half-life (minutes to a few hours), while PEA and butyrate are rapidly metabolized.
- Administration Routes
- subcutaneous, oral
- Research Status
- Research Chemical
Reported Benefits
- Investigated for repair of intestinal epithelial barrier and tight junctions
- May reduce local gastrointestinal inflammation
- Studied for support of the gut mucosal lining
- Combines angiogenic, anti-inflammatory, and metabolic mechanisms
- Explored for symptoms associated with leaky-gut and colitis models
- Potential synergy between systemic and locally acting components
Potential Side Effects
- Gastrointestinal upset, nausea, or altered bowel habits
- Injection-site irritation when administered subcutaneously
- Possible headache or fatigue
- Unknown effects from combining multiple agents
- Limited human safety data for the blend
Common Dosing
For research use only and not personal medical advice; literature on the individual components describes BPC-157 in the ~250-500 mcg range one to two times daily and KPV in the ~200-500 mcg range, with PEA and tributyrin dosed as oral fatty-acid mediators. Blend formulations vary by vendor and lack standardized protocols.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or suspected malignancy due to pro-angiogenic activity
- Pregnancy and breastfeeding
- Known hypersensitivity to any blend component
BPC-157
A synthetic peptide fragment derived from a protein found in gastric juice, studied for its broad tissue-healing and cytoprotective effects. Popular in research for tendon, ligament, muscle, and gut repair.
KPV
KPV is a tripeptide derived from the C-terminus of alpha-MSH that exerts anti-inflammatory effects without pigmentary activity. It is studied for gut inflammation, wound healing, and skin conditions.
TB-500
A synthetic version of the active region of Thymosin Beta-4, a naturally occurring peptide that regulates cell migration and tissue repair. Researched for recovery, flexibility, and wound healing.
N-Acetyl Larazotide
An N-acetylated analog of larazotide acetate, an octapeptide studied as a tight-junction regulator intended to reduce intestinal permeability (leaky gut). The N-acetyl modification is marketed to improve enzymatic stability of the parent peptide.
- View
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
2011
- View
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
2008
- View
Therapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders
2024
- View
Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers
2009